Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Federico Albrecht"'
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Autor:
Miguel A. Villalona-Calero, John P. Diaz, Wenrui Duan, Zuanel Diaz, Eric D. Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Guardiola, Sara Garrido, Muni Rubens, Fernando DeZarraga, Hao Vuong
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-11 (2022)
Abstract Background Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can also influence susceptib
Externí odkaz:
https://doaj.org/article/638687a2c44a4b188f5880b1264f5ad8
Autor:
Samuel Kareff, Leylah Drusbosky, Luis E. Raez, Federico Albrecht, Mike Cusnir, Edgardo Santos, Estelamari Rodriguez
Publikováno v:
Journal of Thoracic Oncology. 18:S4-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1725c2e54cbbfacd539f8849406fa7e6
https://doi.org/10.1016/j.jtho.2023.01.021
https://doi.org/10.1016/j.jtho.2023.01.021
Autor:
Tugce, Kutuk, Haley, Appel, Maria Carolina, Avendano, Federico, Albrecht, Paul, Kaywin, Suyen, Ramos, Melanie E, Suarez-Murias, Minesh P, Mehta, Rupesh, Kotecha
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 2020
Purpose: The objectives of this study were to evaluate the implementation, device usage rates, clinical outcomes, and treatment-related toxicities associated with TTFields and pemetrexed plus platinum-based chemotherapy in patients with unresectable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc70696d2bf45c49fed6c50a4d0cfa89
https://doi.org/10.3390/cancers14082020
https://doi.org/10.3390/cancers14082020
Autor:
Minesh P. Mehta, Evan W. Alley, Paul Kaywin, Haley Appel, M.C. Tom, Rupesh Kotecha, Muni Rubens, Raees Tonse, Federico Albrecht
Publikováno v:
Cancers, Vol 13, Iss 2186, p 2186 (2021)
Cancers
Cancers
Simple Summary Malignant pleural mesothelioma (MPM) is a rare cancer with an aggressive disease course. For patients who are medically inoperable or surgically unresectable, multi-agent systemic therapy remains an accepted standard-of-care around the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a1cd8b0b0a42c0b3f070258c8e4378
https://doi.org/10.3390/cancers13092186
https://doi.org/10.3390/cancers13092186
Autor:
Siddhartha A. Venkatappa, John Paul Diaz, Gail Walker, Zuanel Diaz, Alfredo Pedro Alonso, Miguel A. Villalona-Calero, Santiago Aparo, Muni Rubens, Sara M. Garrido, Sebastian Cuitiva, Hao Vuong, Eric Schroeder, Wenrui Duan, Federico Albrecht, Victor Guardiola, Michael B. Troner, Fernando I. De Zarraga, Troy Antony Gatcliffe
Publikováno v:
Journal of Clinical Oncology. 37:2555-2555
2555 Background: Given the activity of immune checkpoint inhibitors (ICI) in mismatch repair deficient tumors, we evaluated if homologous recombination repair deficiency associates with solid tumor response to ICI. Methods: We conducted a phase 2 tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1a0903adfba38a8d18109fec026937
https://doi.org/10.1200/jco.2019.37.15_suppl.2555
https://doi.org/10.1200/jco.2019.37.15_suppl.2555
Autor:
Miguel Villalona, Federico Albrecht, Vanessa Yanek, Eric Schroeder, Gail Walker, Zuanel Diaz, Wenrui Duan, Fernando Manuel Vargas Madueno, Siddharta Venkatappa, Santiago Aparo, John P. Diaz
Publikováno v:
Journal of Clinical Oncology. 36:TPS3108-TPS3108
TPS3108Background: Recent studies have shown that patients with mismatch repair deficiency have an increased response rate to immune checkpoint inhibitors (ICI). This led to the tissue-agnostic FDA...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b7ac6e71d7d8340202311df73633d60
https://doi.org/10.1200/jco.2018.36.15_suppl.tps3108
https://doi.org/10.1200/jco.2018.36.15_suppl.tps3108
Autor:
Humberto Caldera, Federico Albrecht, Hugo F. Fernandez, Shari Lennon, Hai T Tran, Mark Goodman
Publikováno v:
Biology of Blood and Marrow Transplantation. 8(9):486-492
Intravenous busulfan (i.v. BU) has demonstrated safety when administered at 0.8 mg/kg per dose i.v. every 6 hours x 16 doses. We evaluated the safety and pharmacokinetics (PK) of giving the same total daily i.v. BU dose (3.2 mg/kg) either divided as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b970c5467544608a3910dbe079f49de